This is investment research, not personal financial advice.
Moderna (NASDAQ:MRNA) closed at $174.38 on 19 August 2026, up 176.97% from $62.96, after the company and Merck announced before the open that intismeran autogene plus KEYTRUDA had met its primary endpoint in Phase 3 (Merck & Moderna 2026). The close put $69.6 billion of market value on a company that held $25.1 billion the day before. Volume reached 197.5 million shares against a twenty-day average near 5.4 million, a 36.8x session (StockAnalysis 2026). The catalyst was one paragraph: in the 1,137-patient INTerpath-001 trial in completely resected stage IIB-IV melanoma, the combination beat KEYTRUDA alone on recurrence-free survival, the primary endpoint, and on distant metastasis-free survival, a key secondary, at a prespecified interim analysis. The release contained no hazard ratio, no confidence interval and no survival curves. Those numbers are being held for a future medical meeting.
That gap between what was proved and what was priced is the whole story of this session. This article works through the trial evidence as filed, the economics Moderna actually books under its profit-sharing agreement with Merck, the addressable-population arithmetic, and a reverse-valuation check on what $44.5 billion of added enterprise value requires. The verdict it reaches: the direction of the move is justified by a genuine first in oncology, and the magnitude prices a franchise that melanoma alone cannot supply. Roughly $4-5 billion of the added value is supported by the melanoma indication on conservative assumptions. The remainder depends on trials that have not read out.
The endpoint Moderna cleared, and the number it withheld
INTerpath-001 is the first Phase 3 study of an individualized neoantigen therapy to report, and the first Phase 3 study of any mRNA cancer therapy to succeed. It is also the first regimen to beat KEYTRUDA monotherapy, a standard of care, in the adjuvant melanoma setting. Patients were randomized 2:1 to intismeran at 1 mg every three weeks for up to nine doses plus KEYTRUDA at 400 mg every six weeks, versus KEYTRUDA alone, for roughly a year after surgery. The primary endpoint, recurrence-free survival, measures time to any local, regional or distant recurrence or death from any cause. Distant metastasis-free survival, the key secondary that also hit, measures time to metastatic spread (Merck & Moderna 2026).
What the release did not contain matters as much as what it did. The companies said the improvements were "statistically significant and clinically meaningful" at a prespecified interim, with no new safety signals, and that the study continues to evaluate overall survival and other secondaries. No effect size has been published. The strongest public anchor for the size of the effect remains the Phase 2b KEYNOTE-942 dataset, where five-year follow-up presented at ASCO in June 2026 showed a 49% reduction in the risk of recurrence or death (HR 0.51, 95% CI 0.294-0.887) and a 59% reduction in distant metastasis or death (HR 0.411) for the combination. The original December 2022 readout of that 157-patient Phase 2 was HR 0.56 (Merck & Moderna 2026; Moderna 2026b).
Two aspects of the trial's structure deserve attention. First, this was an interim analysis, and the trial's registry record runs long: primary completion is listed for October 2029 and study completion for September 2030, with recurrence-free survival followed for up to roughly 74 months (ClinicalTrials.gov 2026). The topline arrived four months ahead of even the companies' own "potentially in 2026" guidance, a fact RBC Capital Markets called "surprisingly positive," reasoning that "the strength of the underlying data must have been compelling to trigger significance at the interim" (BioSpace 2026). Interim hits are informative, but they are measured on less mature curves, and regulators will see the full dataset before any approval. Second, overall survival, the endpoint that changed adjuvant melanoma standards a decade ago, is years from reading out. Moderna president Stephen Hoge has argued recurrence-free survival "really is survival" over long horizons, but the Phase 3 trend is not yet public (BioSpace 2026).
From $19,263 million to $1,944 million: the business underneath the spike
The company that tripled on Wednesday is a business whose revenue has fallen 90% in three years. The audited record from the FY2025 Form 10-K and its predecessors:
| Year | Revenue ($M) | Net income ($M) | R&D ($M) | Operating cash flow ($M) | Cash + investments, year-end ($M) |
|---|---|---|---|---|---|
| FY2022 | 19,263 | 8,362 | 3,295 | +4,981 | 18,220 |
| FY2023 | 6,848 | -4,714 | 4,845 | -3,118 | 13,281 |
| FY2024 | 3,236 | -3,561 | 4,543 | -3,004 | 9,519 |
| FY2025 | 1,944 | -2,822 | 3,132 | -1,873 | 8,135 |
| 1H 2026 | 534 | -2,125 | 1,300 | -1,156 | 6,910 (30 Jun) |
All rows are as filed with the SEC; the 1H 2026 net loss includes a $950 million litigation settlement charge booked in cost of sales (Moderna 2023; Moderna 2025; Moderna 2026b; Moderna 2026c). Net product sales were $1,818 million in FY2025, of which $1,810 million was still COVID vaccine, split $1,165 million United States, $50 million Europe and $603 million rest of world; the RSV vaccine mRESVIA contributed $8 million (Moderna 2026b).
Read that table as the pre-event setup. The respiratory franchise that made Moderna a $100 billion company at the 2021 peak has been compounding in reverse. The company has responded with cost cuts, research spending down from $4,845 million in FY2023 to $3,132 million in FY2025 and guided to roughly $2.9 billion for 2026, and a promise of "up to 10% revenue growth" in 2026 on a base of $1,944 million (Moderna 2026d). The July quarter brought the fifth approved product, the seasonal flu vaccine mFLUSIVA, on a 5 August PDUFA date, and a European authorization for the flu-COVID combination mCOMBRIAX. It also brought a failure: the norovirus vaccine mRNA-1403 did not meet statistical criteria for early success at its Phase 3 interim, and the company is enrolling an additional cohort (Moderna 2026d; Moderna 2026a). That miss, announced 31 July, is part of why the shares sat at $62.96, a 52-week range that runs from $22.28, before Wednesday's release (StockAnalysis 2026).
Into that setup arrived the first Phase 3 validation of the technology platform the company has spent thirteen years and, by the cumulative operating cash flow column above, more than $10 billion building.
Splitting every dollar with Merck
The economics Moderna books from intismeran are not the economics of a wholly-owned drug. Under the PCV Collaboration and License Agreement, amended and restated in 2018, Moderna and Merck "will share costs and any profits and losses worldwide related to mRNA-4157 equally" (Moderna 2026b). Every dollar of intismeran operating profit is halved before it reaches Moderna's shareholders, and every dollar of the nine-trial INTerpath development program is a shared cost. The partnership is also the program's greatest asset: KEYTRUDA is the backbone the regimen is built on, and Merck's commercial infrastructure will carry the launch.
The profit-share structure has a consequence for valuation that the day's arithmetic glossed over. If intismeran reaches $4 billion of worldwide sales at a 70% incremental margin, the collaboration earns $2.8 billion of operating profit; Moderna's share is $1.4 billion, roughly $1.1 billion after tax. That is the entire P&L contribution from a drug doing $4 billion, before Moderna's share of launch and development costs. A dollar of intismeran sales is worth roughly half a dollar of a comparable wholly-owned product to Moderna, and the market's Wednesday math has to clear that hurdle twice, once for the 50% split and once for the probability stack behind it.
48,000 patients a year, maybe
The addressable-population arithmetic for the approved indication starts with the cancer registry. Melanoma of the skin is diagnosed at 22.3 per 100,000 Americans per year, roughly 74,700 new cases on a 335 million population. The SEER stage distribution is 77% localized, 10% regional, 5% distant, 9% unstaged (NCI 2026). The trial population is narrower than "melanoma": completely resected stage IIB-IV cutaneous disease, systemically untreated, treated in the adjuvant setting. Stage III (regional) contributes about 7,500 US patients a year; stage IIB/IIC, the thick or ulcerated primaries inside the localized bucket, is on the order of 20% of localized cases; only a fraction of metastatic presentations are completely resected. A defensible author estimate is roughly 21,000 eligible patients a year in the United States, and perhaps 48,000 a year worldwide in launch markets. These are computed figures, not company disclosures, and they should be treated as such.
Pricing has not been set. Each course is manufactured individually from a patient's own tumour mutations, up to 34 neoantigens per therapy, dosed nine times over about six months alongside roughly a year of pembrolizumab (Merck & Moderna 2026). A year of adjuvant KEYTRUDA lists above $100,000 in the United States; an individualized therapy on top of it plausibly prices in the $100,000-150,000 range at launch, with European and other payer markets materially lower. At $120,000 net worldwide blended and 30% penetration of the estimated eligible population by the early 2030s, worldwide sales peak near $1.7 billion. Halve the margin split and tax the remainder, and Moderna's share of the peak economics is roughly $0.5 billion a year of after-tax profit. Discounted back five years at 10%, capitalised at 18 times and probability-weighted at 85% for post-Phase 3 regulatory success, the melanoma indication supports something like $4-5 billion of value. That is real money, and it is a tenth of Wednesday's move.
The gap closes only through the rest of the program. INTerpath now spans nine Phase 2 and Phase 3 trials: melanoma (read), a Phase 3 in high-risk stage 1 non-small cell lung cancer announced in the June quarter covering intismeran as monotherapy and with KEYTRUDA QLEX, fully enrolled Phase 2 trials in adjuvant renal cell carcinoma and muscle-invasive bladder cancer, and earlier work (Moderna 2026d; Merck & Moderna 2026). Lung cancer is the prize. Resected high-risk stage 1 NSCLC is a multiple of melanoma's eligible population, and a second Phase 3 win there would convert the platform from a one-indication story into an engine. But no NSCLC Phase 3 data exist yet. BioNTech, the closest platform comparable, rose 21.96% to $113.12 on the read-through, and Merck, which books the other half of the economics plus the KEYTRUDA upside, rose about 6% to a record intraday high (Finance API 2026; The Pharma Letter 2026). The relative sizes of those moves are their own commentary: the market gave the whole Franchise's worth of credit to the 50% partner with the declining balance sheet.
A $44.5 billion receipt
Run the reverse valuation. Before Wednesday, Moderna carried an enterprise value of roughly $18.8 billion: $25.1 billion of equity value less $6.3 billion of net cash, the latter being $6.91 billion of cash and investments at 30 June against $600 million of drawn term-loan principal. After the close, enterprise value was roughly $63.3 billion (StockAnalysis 2026; Moderna 2026c). The incremental $44.5 billion is what the session added. To support it, Moderna needs $3.4-4.4 billion a year of steady-state after-tax profit attributable to the program, assuming 9-10% discount rates, five to six years to maturity and 18-22 times terminal earnings, all author assumptions. Through the 50/50 split and tax, that requires the collaboration to generate $12-16 billion of worldwide peak sales at rich incremental margins.
For scale: that is not a melanoma drug's profile. It is the profile of a front-line franchise across multiple tumour types at once, comparable in today's oncology only to the largest checkpoint-inhibitor franchises. William Blair upgraded the shares on Wednesday on a "clear line of sight to revenue diversification" (BioSpace 2026), and directionally they are right that the probability of diversification just jumped. But a line of sight is not a launch, and the model above says roughly a quarter of the move is covered by generous probabilities on the disclosed program, with the balance requiring either pricing well above $150,000, penetration well above a third of eligible patients, or NSCLC success being closer to certain than to coin-flip.
Four scenarios, built from those drivers and expressed per share on roughly 405 million diluted shares:
| Case | Core assumptions | Value per share |
|---|---|---|
| Severe downside | Weak disclosed effect (HR ~0.75-0.85), regulatory delay, norovirus fails again, burn unchanged | $55-75 |
| Bear | HR 0.65-0.75, melanoma-only approval 2028, slow launch, no credit for other tumours | $85-115 |
| Base | Effect consistent with Phase 2b five-year HR 0.51, filing 2027, approval 2028, 25-35% penetration, partial NSCLC credit | $135-175 |
| Bull | HR at or below 0.55 with positive OS trend, expedited filing, approval 2027, NSCLC succeeds by 2028 | $230-320 |
The base band brackets the low $140s to $175; the closing price sits at its top edge. On this arithmetic the market has paid full price for a scenario in which the undisclosed hazard ratio looks like the Phase 2b five-year data and the rest of the program mostly works.
The cash bridge still runs downhill
The balance sheet story did not change on Wednesday, but the cost of fixing it did. Cash and investments were $6.9 billion at 30 June; the company paid the $950 million Arbutus/Genevant patent settlement in July; management guides to $4.7-5.2 billion at year-end 2026 (Moderna 2026c; Moderna 2026d). The burn has slowed, from $3.0 billion of operating cash use in FY2024 to $1.9 billion in FY2025, but the queue in front of any intismeran revenue is long: a regulatory filing built on interim data, a potential advisory committee, launch manufacturing for a therapy made one patient at a time, and the rest of the nine-trial program. Author projection on current guidance: roughly $3 billion of cash at end-2027 and $1.5-2 billion at end-2028 before any oncology revenue, with a further $400 million available under the delayed-draw facility through November 2027 and $500 million more gated on regulatory approval milestones through November 2028 (Moderna 2026c). At $62.96, funding that path meant issuing perhaps 10% of the company. At $174.38, the same raise costs under 3%, and the milestone-gated tranche now has a visible trigger. The rally is, among other things, a financing event.
That cuts both ways. The equity's ability to absorb dilution improved threefold in a session, which lowers the risk that shareholders are diluted at the bottom. It does nothing for the operating burn itself, and the monitoring plan below keeps the cash line, not the share price, as the survival metric.
Four facts that decide it
The crux facts, with the calendar that resolves them. First, the effect size: hazard ratios for recurrence-free and distant metastasis-free survival at the upcoming medical meeting. If the Phase 3 interval lands near the Phase 2b five-year 0.51, the base case holds; if it drifts toward 0.8 with intervals brushing 1.0, the market's Wednesday assumption of durable, large benefit needs re-testing. Second, the regulatory path: the companies have said they will share data with regulators, and filing an interim recurrence-free survival dataset in an adjuvant indication is a strategy with precedent but also with advisory-committee risk; the primary-completion date of October 2029 is the backstop if regulators want maturity (ClinicalTrials.gov 2026). Third, overall survival: the endpoint that determines whether "clinically meaningful" becomes a label claim, reading out over years. Fourth, cash: the $4.7-5.2 billion year-end guide against a burn that has consumed more than $11 billion of liquidity since the end of 2022.
The market's verdict on Wednesday, on this evidence, was right in direction and aggressive in magnitude. A genuine first-in-class Phase 3 success re-priced the probability that Moderna's platform produces oncology economics, and roughly the first $10-15 billion of the move maps to melanoma plus a reasonable option on earlier-stage trials. The last $25-30 billion is a wager that individualized neoantigen therapy scales across tumour types at prices the payer system accepts, at manufacturing cost structures that have never been tested at commercial volume, disclosed so far only as the words "statistically significant." The after-hours session, which traded the stock back to $162.74 by 6:33 pm ET, suggests the market itself is beginning that argument (StockAnalysis 2026). The number that settles it, the hazard ratio, arrives at a medical meeting that has not yet been named.
Source notes, confidence and what is missing
The joint press release was read in full via its Business Wire syndication; the canonical businesswire.com URL was unreachable from this environment, and the Yahoo Finance syndication carried the complete text, confirmed against Merck's and Moderna's own summaries. The financial statements were taken from the SEC-filed Form 10-K documents for FY2022, FY2024 and FY2025 and the Form 10-Q for Q2 2026, each opened and checked directly; FY2023 figures appear as comparatives in the FY2025 10-K. Market data for MRNA is the StockAnalysis.com compilation of the 19 August Nasdaq close; the point-in-time Finance API packet for MRNA had not ingested the 19 August bar at the time of writing, an ingestion lag identified and reconciled against the API's 18 August close ($62.96), which exactly matches the implied previous close of the session data used here. BioNTech's session close came from the same API. The following are author computations, not company disclosures: the eligible-population estimate and its SEER inputs, the $120,000 blended net price, the penetration and margin assumptions, the melanoma risk-adjusted present value, the reverse-valuation requirements, the scenario bands and the 2027-28 cash projection. Merck's closing price on 19 August was not independently retrievable from primary sources in this environment; the roughly 6% intraday gain is reported by The Pharma Letter and labelled accordingly. No Phase 3 effect size exists in the public domain; any statement about the strength of the effect beyond "met the endpoint" is inference, flagged as such above. Verification is partial for these reasons.
References
- BioSpace 2026, 'Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal', 19 August.
- ClinicalTrials.gov 2026, study record NCT05933577, Phase 3 INTerpath-001 (V940-001).
- Finance API 2026, Daily Finance price packet for BioNTech SE (BNTX), 19 August session.
- Merck & Moderna 2026, joint press release, positive topline results from Phase 3 INTerpath-001, 19 August.
- Moderna 2023, Form 10-K, year ended 31 December 2022.
- Moderna 2025, Form 10-K, year ended 31 December 2024.
- Moderna 2026a, IR Insights, recapping positive Phase 3 topline results for intismeran autogene plus pembrolizumab, 19 August.
- Moderna 2026b, Form 10-K, year ended 31 December 2025.
- Moderna 2026c, Form 10-Q, quarter ended 30 June 2026.
- Moderna 2026d, second quarter 2026 results release (8-K Exhibit 99.1), 31 July.
- NCI 2026, SEER Cancer Stat Facts: melanoma of the skin.
- SEC 2026, EDGAR company record for Moderna, Inc. (MRNA).
- StockAnalysis 2026, Moderna (MRNA) market page, 19 August close.
- The Pharma Letter 2026, 'Merck and Moderna announce Phase III INTerpath-001 trial of intismeran combo', 19 August.